Anti-HIV Proteins GAP 31, DAP 30 And DAP 32 And Therapeutic Uses Thereof


GAP 31, a 31 kDa protein, and DAP 30 and 32, 30 and 32 kDa proteins, respectively, which may be purified from extracts of Gelonium multiflorum (a medicinal plant) and Dianthus caryophyllus (carnation), respectively, or produced by recombinant DNA technology, are useful in treating HIV infection. GAP 31 also exhibits anti-tumor activity. These proteins belong to the family of single-chain ribosome-inactivating proteins (SCRIPS), which inactivate ribosomes in cell-free systems but are relatively nontoxic to intact cells. The biological properties of GAP 31 include: (1) N-glycosidase activity on 28S ribosomal RNA; (2) topological activity on plasmid and viral DNAs including HIV-1 LTRs; and (3) dose-dependent inhibition of HIV-1 integrase. The cloning and expression of the genes encoding biologically active recombinant GAP31, and DAP 30 and 32 provides an abundant source of homogeneous material for clinical investigations. The patent discloses purified natural and recombinant proteins, processes for purifying the proteins, DNA sequences encoding the proteins, and recombinant methods for expressing the proteins.

Related Invention(s):
E-190-1990/0
E-085-1992/0


Inventors:

Sylvia Lee-huang

Intellectual Property:
U.S. Pat: 5,317,009 issued 1994-05-31
US Application No. PCT/US92/07142

Publications:
S Lee-Huang et al., "Proteolytic fragments of anti-HIV proteins MAP30 and GAP31 are biologically active," XI International Conference on AIDS (abstract) (1996)
S Lee-Huang et al., "Inhibition of the integrase of human immunodeficiency virus (HIV) by anti-HIV plant proteins MAP30 and GAP31," Proc. Natl. Acad. Sci. 92: 8818-8822 (1995)

Licensing Contact:
Lauren Nguyen-Antczak, Ph.D., J.D.
Email: lauren.nguyen-antczak@nih.gov
Phone: 301-624-8752

OTT Reference No: E-061-1992/0
Updated: Oct 1, 1996